Modality
Fusion Protein
MOA
AHRant
Target
WEE1
Pathway
PD-1/PD-L1
GA
Development Pipeline
Preclinical
~Sep 2017
→ ~Dec 2018
Phase 1
~Mar 2019
→ ~Jun 2020
Phase 2
Sep 2020
Phase 2Current
NCT05149741
2,869 pts·GA
2020-09→TBD·Completed
2,869 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-08-197mo agoEnrollment Complete· GA
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P2
Complet…
Catalysts
Enrollment Complete
2025-08-19 · 7mo ago
GA
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05149741 | Phase 2 | GA | Completed | 2869 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| BII-5449 | Biogen | Phase 3 | FXIa | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| Elratapinarof | Halozyme | Phase 2 | C5 | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| NTL-2576 | Intellia | NDA/BLA | SGLT2 | |
| Bemavorutinib | Acadia Pharma | Phase 1/2 | WEE1 |